The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results